Arthritis. Alzheimer's Disease. Cancer. Diabetes Fragile X. Infectious Disease. Muscular Dystrophy. Autism. Hepatitis Vaccine Safety. These are among our nation's leading public health issues that our health and life sciences team has helped raise to a national focus in the eyes of leaders in Congress and at both Centers for Disease Control (CDC) and National Institutes of Health (NIH). In the world of public health, hundreds of worthy causes are competing for increasingly scare public health and research dollars. Without solid and specific plans of action and strong support among leaders in Congress, it's increasingly difficult for research and voluntary health communities, including patient groups, practicing clinicians, public health agencies and industry, to gain the attention — and financial commitment — they need.

With one of the nation's leading public health policy practices, FaegreBD Consulting has developed a multitude of programs involving the CDC, state health departments and private sector partners. From developing initial strategies to helping organize large-scale advocacy efforts including "fly-ins," to working with the senior officials at the CDC and NIH, our team is capable of supporting a wide range of stakeholders, including small rare-disease groups and large advocacy organizations from very small rare disease organizations to large-scale multi-million dollar advocacy groups. Our professionals have established deep and long-term relationships with public health and research leaders, including current and former directors of the NIH and CDC.

Working With Federal Health Agencies

FaegreBD Consulting has proven experience working with federal agencies, specifically Centers for Disease Control (CDC), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA), and Centers for Medicare and Medicaid Services (CMS), and with public health stakeholder groups on a wide variety of projects aimed at enhancing the nation's public health.

FaegreBD Consulting knows that to be successful at CDC and NIH and other governing agencies, VHAs need the full support of both Congressional leaders and agency officials. That's why our work goes far beyond the Congressional appropriations process and focuses on building lasting relationships at the agencies where our clients partner with federal officials to address common challenges. Additionally, FaegreBD Consulting has accumulated significant experience in helping VHAs enter into cooperative agreements with federal agencies to ensure dedicated federal funding is applied toward a specific project, leveraging further every private dollar brought to the table by the stakeholders.

At the CDC, FaegreBD Consulting has played a critical role in providing technical assistance to clients for several projects, including the Autism Epidemiology and Surveillance initiative, the national center for limb loss information, the physical activity for people with disabilities program, the National Arthritis Action Plan and the Fragile X initiative to name a few. FaegreBD Consulting professionals have been longtime active members of the agency's external partners group, have been actively engaged in the recent reorganization under the Futures Initiative and have played a leading role in the development of the Agency's Health Protection Goals.

Finally, we have assisted clients with various phases of the design drafting and execution of Cooperative Agreements with the CDC. Regardless of size and scope, these agreements include a number of constants such as the development of evaluation models, the selection on an external evaluator, new mechanisms for measuring health impact, and clear expectation for agency and client performance.

We have an unsurpassed record of assisting clients in planning and implementing partnerships with many of the various institutes at the NIH. We work to engage NIH staff in dialogues and collaborative activities on behalf of our clients. We develop Congressional strategies to enhance and intensify the research dollars spent on biomedical research at the NIH and stimulate the translation of these research findings into public health practice.